Phathom Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated product revenue of $58.3 million, a substantial increase from $28.5 million in the same period last year, reflecting a growth of 104%. This increase is attributed to the successful commercialization of its VOQUEZNA product line, which includes VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK, launched in late 2023. The gross profit for the quarter was $46.3 million, compared to $24.8 million in the prior year, indicating improved operational efficiency.
Operating expenses for the quarter totaled $61.8 million, down from $103.7 million in the previous year, primarily due to a significant reduction in selling, general, and administrative expenses, which fell from $94.5 million to $54.0 million. This reduction was largely driven by a $36.9 million decrease in advertising and promotional costs, as well as lower personnel-related expenses. The company reported a net loss of $30.4 million for the quarter, a notable improvement from the $94.3 million loss recorded in the same period last year.
Phathom's balance sheet showed total assets of $305.1 million as of March 31, 2026, up from $259.1 million at the end of 2025. Cash and cash equivalents increased to $180.9 million, compared to $130.0 million at the end of the previous year. The company’s liabilities decreased to $642.1 million from $697.3 million, primarily due to a reduction in long-term debt following a refinancing agreement with Hercules Capital, which provided a new term loan of $175 million. This refinancing extended the maturity date of the loan and eliminated the payment-in-kind interest rate, improving the company’s cash flow position.
Operationally, Phathom has seen a rise in prescription volume, with approximately 1.35 million prescriptions filled for its VOQUEZNA products since launch. The company has also achieved broad commercial coverage, with access for over 120 million U.S. commercial lives. Looking ahead, Phathom anticipates reaching operating profitability by the third quarter of 2026, excluding stock-based compensation, contingent on continued revenue growth from its product lines. However, the company acknowledges the inherent uncertainties in achieving these projections and may need to seek additional funding to support its operations and growth strategies.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals develops and commercializes novel gastrointestinal treatments, primarily focusing on vonoprazan, a potent, fast-acting potassium-competitive acid blocker. Its core products target acid-related GI diseases such as GERD and H. pylori infection. The company emphasizes innovative therapies with improved efficacy over traditional PPIs, leveraging a differentiated mechanism of action, and aims to expand indications and formulations in the U.S. and international markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.